Sanofi (SNY) 6-K Information on Q1 2018 Financial Results

Exhibit 99.2

RECENT DEVELOPMENTS

Unaudited Consolidated Balance Sheet as at March 31, 2018

Set forth below is the unaudited consolidated balance for Sanofi as at March 31, 2018 and December 31, 2017.

ASSETS

(€ million)	March 31, 2018		December 31, 2017(1)
Property, plant and equipment		9,356		9,579
Goodwill		41,194		40,264
Other intangible assets		21,008		13,080
Investments in associates and joint ventures		2,786		2,847
Othernon-current assets		3,311		3,364
Deferred tax assets		4,238		4,291
Non-current assets		81,893		73,425
Inventories		7,036		6,818
Accounts receivable		6,389		7,216
Other current assets		2,203		2,005
Cash and cash equivalents		12,799		10,315
Current assets		28,427		26,354
Assets held for sale or exchange		1,343		34
TOTAL ASSETS		111,663		99,813

(1) Including impacts of IFRS15 implementation on revenue recognition.

EQUITY AND LIABILITIES

(€ million)	March 31, 2018		December 31, 2017(1)
Equity attributable to equity holders of Sanofi		58,088		58,070
Equity attributable tonon-controlling interests		165		169
Total equity		58,253		58,239
Long-term debt		21,460		14,326
Non-current liabilities related to business combinations and tonon-controlling interests		1,107		1,026
Non-current provisions and othernon-current liabilities		8,713		9,154
Deferred tax liabilities		3,292		1,605
Non-current liabilities		34,572		26,111
Accounts payable		4,330		4,633
Current liabilities related to business combinations and tonon-controlling interests		340		343
Other current liabilities		8,329		9,212
Short-term debt and current portion of long-term debt		5,542		1,275
Current liabilities		18,541		15,463
Liabilities related to assets held for sale or exchange		297		—
TOTAL EQUITY AND LIABILITIES		111,663		99,813

(1) Including impacts of IFRS 15 implementation on revenue recognition.

Other Recent Events

In addition to the information included under “Information on Q1 2018 Financial Results” in Exhibit 99.1, Sanofi has reported the following recent developments:

• On April 24, 2018, Sanofi announced that Elias Zerhouni, M.D., Head of Global Research and Development, will retire from Sanofi effective June 30, 2018, and will be succeeded by John C. Reed, M.D. Ph.D. effective as of July 1, 2018.

• On May 2, 2018, Sanofi’s shareholders approved resolutions submitted for a vote at the Combined General Shareholders’ Meeting. In particular, the shareholders approved the distribution of a cash dividend of €3.03 per share, with a total payment of €3.8 billion made on May 15, 2018. The General Meeting also renewed the appointment of Directors Olivier Brandicourt, Patrick Kron and Christian Mulliez and approved the appointment of Emmanuel Babeau as independent Director, for a term of four years.

• On May 14, 2018, Sanofi announced the results of its tender offer for all the outstanding shares of Ablynx, a Belgian company, which resulted in Sanofi owning 95.60% of the outstanding shares of the company. Ablynx, whose ordinary shares are listed on Euronext Brussels and whose American Depositary Shares are listed on NASDAQ, is engaged in the development of nanobodies. Settlement of the tender offer occurred on May 18, 2018 for €3.7 billion. Sanofi also commenced thesqueeze-out procedure to acquire those securities not previously tendered in the offers. Thesqueeze-out period will expire on June 12, 2018. In connection with the tender offer, Sanofi entered into a €4.2 billion term facility agreement with BNP Paribas Fortis SA/NV on January 28, 2018, which agreement was amended on March 29, 2018. On May 25, 2018, Sanofi reduced the amount of the term facility to €200 million, which is expected be canceled without being drawn, upon completion of thesqueeze-out procedure.

• Between March 31, 2018 and June 8, 2018, Sanofi has issued U.S. commercial paper for a total consideration of $6.1 billion and has repaid $4.5 billion of the issued commercial paper, resulting in a net increase of $1.7 billion of Sanofi’s outstanding commercial paper.

• On June 11, 2018, Sanofi launched its Action 2018 Shareholding Plan, pursuant to which Sanofi may sell up to 0.5% of its ordinary shares to its eligible employees.